Enlivex Receives FDA IND Clearance for Phase 2b Allocetra Trial in Knee Osteoarthritis

summarizeSummary

Enlivex Ltd. announced FDA clearance of its Investigational New Drug (IND) application for Allocetra™ to begin a global Phase 2b clinical trial for moderate-to-severe knee osteoarthritis, marking a significant advancement in its clinical pipeline.

check_boxKey Events

• FDA IND Clearance Received

  The U.S. Food and Drug Administration (FDA) has cleared Enlivex's Investigational New Drug (IND) application for Allocetra™.

• Phase 2b Clinical Trial Authorized

  This clearance enables Enlivex to initiate a global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial for Allocetra™.

• Targeting Knee Osteoarthritis

  The trial will evaluate Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, a prevalent and disabling disease with limited treatment options.

• Follows Positive Prior Data

  The IND clearance follows positive 3 and 6-month data from the Company's Phase 1/2a clinical trial, which demonstrated a robust and durable treatment effect in older patients.

auto_awesomeAnalysis

This FDA Investigational New Drug (IND) clearance is a significant positive development for Enlivex, allowing its lead immunotherapy, Allocetra™, to advance into a global Phase 2b clinical trial for moderate-to-severe knee osteoarthritis. This milestone validates the drug's potential following positive Phase 1/2a data and targets a large patient population with substantial unmet medical needs. The successful progression of this trial could significantly de-risk the asset and enhance the company's long-term value proposition, aligning with its stated 'quality longevity program'.